Physicians' Academy for Cardiovascular Education

Guidance for an individualized statin intolerance approach

5' education - Jan. 30, 2023 - Prof. Maciej Banach, MD, PhD

Treating iron deficiency in patients with HFrEF: A review of the recent data for IV iron replacement therapy

10' education - Jan. 5, 2023 - Prof. Javed Butler, MD, Prof. Stefan Anker, MD, PhD, Piotr Ponikowski, MD, PhD, and Robert J. Mentz, MD

Inflammation as a new target in CV risk reduction

10' education - Dec. 13, 2022 - Prof. Paul Ridker, MD

Findings of a trial with pemafibrate in a contemporary patient population

5' education - Dec. 7, 2022 - Prof. Paul Ridker, MD

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD

Mechanistic clues to understanding the benefits of icosapent ethyl

10' education - Nov. 28, 2022 - Prof. Matthew Budoff, MD

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra

Applying GDMT for iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD

Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Why ischemia matters when it comes to iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD

How to choose the optimal therapy?

10' education - Nov. 17, 2022 - Prof. Kausik Ray, MD

The role of potassium binders in optimal HF management: Discussing the DIAMOND study

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs

15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Effects of a guideline-based approach on achieving LDL-c goals

3' education - Nov. 14, 2022 - Aaram Omar Khader, MD

LDL-c: new insights into its role as causal risk factor and target for therapy

10' education - Nov. 11, 2022 - Prof. Brian Ference, MD

LDL-c goal attainment after STEMI with early combination therapy

Literature - Feb. 2, 2023 - Makhmudova U et al. - Clin Res Cardiol. 2023

With early initiation of atorvastatin 80 mg plus ezetimibe 10 mg, and escalation with bempedoic acid or PCSK9i if needed, all 85 patients hospitalized for STEMI achieved the 2019 ESC/EAS Guidelines LDL-c target.

DAPT for ≤3 months after PCI effective and safe in high bleeding risk patients

Literature - Feb. 2, 2023 - Costa F, et al. - Eur Heart J. 2022

The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention is an extensive topic of debate in patients at high bleeding risk. This systematic review and meta-analysis provides more clarity.

Guidance for an individualized statin intolerance approach

5' education - Jan. 30, 2023 - Prof. Maciej Banach, MD, PhD
Prof. Maciej Banach and colleagues have written a guidance paper on individualized therapy in patients with statin intolerance. Prof. Banach presents the steps on how to effectively diagnose and treat statin intolerance.

Prof. Maciej Banach and colleagues have written a guidance paper on individualized therapy in patients with statin intolerance. Prof. Banach presents the steps on how to effectively diagnose and treat statin intolerance.

Effect of SGLT2 inhibitor on CV death or HF hospitalization in HFpEF independent of SBP

Literature - Jan. 30, 2023 - Böhm M, et al. - Eur Heart J. 2022

The SGLT2 inhibitor empagliflozin reduces the risk of cardiovascular death or first hospitalization for HF in patients with HF and an LVEF >40%, compared with placebo. It is unclear whether this effect is modified by SBP.

Polygenic risk score for CAD especially useful in younger adults

Literature - Jan. 30, 2023 - Marston NA et al. - JAMA Cardiol. 2022

In a longitudinal, population-based cohort study, a polygenic risk score for coronary artery disease (CAD) had greatest predictive power in participants aged <50 years. Additionally, several individuals were reclassified, which affected their eligibility for statin therapy.

SGLT2i reduces specific causes of CV death in HF across wide LVEF spectrum

Literature - Jan. 30, 2023 - Desai AS et al. - JAMA Cardiol. 2022

This pooled analysis of the DAPA-HF and DELIVER trials showed a 14% lower risk of CV death with dapagliflozin versus placebo regardless of LVEF, mainly due to lower, albeit nonsignificant, rates of sudden death and HF death.

Risk stratification tool improves outcomes in acute HF

Literature - Jan. 23, 2023 - Lee DS et al. - N Engl J Med. 2023

When a risk stratification tool was used to decide in the ED whether patients with acute HF were discharged or admitted, the risk of all-cause mortality or hospitalization for CV causes was reduced compared with usual care.

PCSK9 siRNA effective and safe in high-risk patients with elevated LDL-c irrespective of PVD status

Literature - Jan. 23, 2023 - Koenig W, et al. - Cardiovasc Drugs Ther. 2022

Patients with polyvascular disease (PVD) have a very high cardiovascular risk and require intensive lipid-lowering therapy. This post-hoc analysis (ORION-9, ORION-10 and ORION-11) examined the efficacy and safety of inclisiran in patients with and without PVD.

Early and sustained clinical benefits with SGLT2i in HFmrEF/HFpEF

Literature - Jan. 23, 2023 - Vaduganathan M et al. - JAMA Cardiol. 2022

A prespecified analysis of the DELIVER trial showed early (<2 weeks) and sustained (>2 years) reductions in CV death or worsening HF with dapagliflozin compared with placebo in patients with HFmrEF or HFpEF.

Phase 2 trial with CETP inhibitor combined with ezetimibe meets primary endpoint

News - Jan. 18, 2023

The ROSE2 trial with obecitrapib in combination with ezetimbe as an adjunct to high-intensity statin met its primary endpoint of LDL-c reduction.

Lower LDL‐c levels associated with CV and renal benefits in moderate CKD under statin treatment

Literature - Jan. 16, 2023 - Yen CL et al. - J Am Heart Assoc. 2022

A Taiwanese observational study evaluated CV and renal outcomes in statin-treated patients with stage 3 CKD across different LDL‐c levels.

FDA approves label update of GLP-1RA as first-line option for T2DM

News - Jan. 16, 2023

A label update for the GLP-1RA semaglutide has been approved by the FDA, which allows use of semaglutide as a first-line option for adults with T2DM.

Agenda